Skin Cancer News and Research

Latest Skin Cancer News and Research

Effective health messaging varies depending on target audience

Is it better to tell people about the harms of certain health decisions or about the benefits of positive health related decisions? Studies that delve into this very question have differing results, however, a new paper just published by Cornell Food & Brand Lab in Nutrition Reviews, finds that the type of health messaging that is most effective might vary depending on certain characteristics of the target audience.

15 Jan 2015

Children of melanoma survivors need better sun protection, says UCLA researchers

In a groundbreaking new study, UCLA researchers have discovered that children of melanoma survivors are not adhering optimally to sun protection recommendations. This is concerning as sunburns are a major risk factor for melanoma, and children of survivors are at increased risk for developing the disease as adults.

14 Jan 2015

British Skin Foundation urges people to check their loved ones moles this Valentine’s Day

Valentine’s Day is fast approaching and this year the British Skin Foundation is urging people to check your loved ones moles! Whether it’s your boyfriend, girlfriend, spouse, friend or family – take the time to check for changes in moles.

12 Jan 2015

ULB researchers uncover new mechanism involved in tumour initiation, growth in SCC

Researchers at the Université libre de Bruxelles (Belgium) report the mechanisms regulating the different functions of Twist1 controlling skin tumour initiation, cancer stem cell function and tumor progression.

12 Jan 2015

Luck is a key factor in cancer development

A statistical model that measures the proportion of cancers that develop as a result of random mutations occurring during cell division was published in Science today.

2 Jan 2015

Johns Hopkins scientists create statistical model to measure proportion of cancer incidence

Scientists from the Johns Hopkins Kimmel Cancer Center have created a statistical model that measures the proportion of cancer incidence, across many tissue types, caused mainly by random mutations that occur when stem cells divide.

2 Jan 2015

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.

31 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Organovo, Yale collaborate to develop bioprinted tissues for surgical transplantation research

Organovo Holdings, Inc., a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, and Yale School of Medicine, Department of Surgery have formed a collaboration to develop bioprinted tissues for surgical transplantation research, made possible by a generous gift from the Methuselah Foundation.

3 Dec 2014

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects.

2 Dec 2014

$Scientists use TPF-SHG microscopy to study effects of micro-ablative fractional laser resurfacing$

Scientists use TPF-SHG microscopy to study effects of micro-ablative fractional laser resurfacing

Many people in the Western World consider it as a social need to hide the effects of aging. For this purpose, different cutaneous rejuvenation treatments have been developed, including a laser-based technique, known as laser resurfacing.

20 Nov 2014

Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma (EWS) and that define a subtype of the cancer associated with reduced survival.

13 Nov 2014

Breakthrough study shows novel molecular imaging drug to detect early prostate cancer

A novel study demonstrates the potential of a novel molecular imaging drug to detect and visualize early prostate cancer in soft tissue, lymph nodes and bone. The research, published in the November issue of the Journal of Nuclear Medicine, compares the biodistribution and tumor uptake kinetics of two Tc-99m labeled ligands, MIP-1404 and MIP-1405, used with SPECT and planar imaging.

11 Nov 2014

JPRAS Open: New open access journal from Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce the launch of a new, online-only open access journal, JPRAS Open .

10 Nov 2014

EKF Molecular Diagnostics to present at AMP annual meeting

EKF, announces that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology.

From EKF Diagnostics 6 Nov 2014

DOST imaging may help predict tumor response before starting treatment

A Dartmouth study suggests that it may be possible to use Diffuse Optical Spectroscopic Tomographic imaging (DOST) to predict which patients will best respond to chemotherapy used to shrink breast cancer tumors before surgery. These findings could eliminate delays in effective early treatment for tumors unlikely to respond to neoadjuvant chemotherapy (NAC).

27 Oct 2014

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc.

20 Oct 2014

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer.

16 Oct 2014

Skin Cancer News and Research

Latest Skin Cancer News and Research

Effective health messaging varies depending on target audience

Children of melanoma survivors need better sun protection, says UCLA researchers

British Skin Foundation urges people to check their loved ones moles this Valentine’s Day

ULB researchers uncover new mechanism involved in tumour initiation, growth in SCC

Luck is a key factor in cancer development

Johns Hopkins scientists create statistical model to measure proportion of cancer incidence

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Organovo, Yale collaborate to develop bioprinted tissues for surgical transplantation research

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

Scientists use TPF-SHG microscopy to study effects of micro-ablative fractional laser resurfacing

Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

Breakthrough study shows novel molecular imaging drug to detect early prostate cancer

JPRAS Open: New open access journal from Elsevier

EKF Molecular Diagnostics to present at AMP annual meeting

DOST imaging may help predict tumor response before starting treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Skin Cancer News and Research

Latest Skin Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in